Nicholson Nur 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 30, 2026
Research Summary
AI-generated summary of this filing
Apellis CTO Nicholson Nur Receives 45,220-Share RSU Award
What Happened
Nicholson Nur, Chief Technical Officer of Apellis Pharmaceuticals (APLS), was awarded 45,220 restricted stock units (RSUs) on January 28, 2026. The Form 4 reports an acquisition price of $0.00 (grant); the filing shows the award quantity but does not state a cash value for the grant.
Key Details
- Transaction date: 2026-01-28; transaction reported on Form 4 filed 2026-01-30 (timely).
- Transaction type/code: A (Award/Grant). Price reported: $0.00.
- Shares/units granted: 45,220 RSUs.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote: RSUs vest 25% annually over four years from the grant date, subject to continued service (per footnote F1).
- No tax-withholding, sale, 10b5-1 plan, or late-filing flag indicated in the excerpt.
Context
RSU grants are a form of compensation/retention for executives and vest over time; they are not market purchases or sales and therefore are not direct bullish or bearish trading signals. Retail investors should view this as executive compensation tied to continued service and potential long-term alignment with shareholders, rather than an immediate insider market bet.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-28+45,220→ 116,338 total
Footnotes (1)
- [F1]This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.